Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $795.00 Price Target at Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by investment analysts at Cantor Fitzgerald from $750.00 to $795.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 7.61% from the stock’s previous close.

REGN has been the topic of a number of other research reports. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Truist Financial raised their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday. HSBC reduced their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Barclays lowered their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $791.96.

Regeneron Pharmaceuticals Price Performance

REGN traded up $0.44 during trading on Friday, reaching $738.78. The company’s stock had a trading volume of 177,474 shares, compared to its average volume of 854,558. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $640.66 and a two-hundred day simple moving average of $711.35. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $821.11. The company has a market cap of $78.10 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 27.78 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the firm posted $12.81 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals will post 2.06 EPS for the current year.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. WPG Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $29,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q2 results: Regeneron reported non-GAAP earnings of $14.29 per share, well above the approximately $10.16 consensus estimate, while revenue rose 16.7% year over year to $4.29 billion, surpassing expectations. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Core products delivered powerful growth: Dupixent sales, recorded by partner Sanofi, increased 38% to a record $6.0 billion, while U.S. EYLEA HD sales jumped 52% to a record $596 million. Libtayo sales also rose 30% to $489 million, helping offset declines in the original EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Additional shareholder return and pipeline support: The company declared a quarterly dividend of $0.94 per share. Investors are also watching potential long-term growth from investigational food-allergy therapies and a collaboration with Telix Pharmaceuticals to develop radiopharmaceutical oncology treatments.
• Neutral Sentiment: Valuation remains debated: Despite a roughly 36% gain over the past year and a trailing price-to-earnings ratio near 18, analysts characterize REGN as neither an obvious bargain nor clearly overvalued, leaving future pipeline execution and earnings growth central to the outlook. Regeneron Stock Looks Cheap On Earnings Yet Mixed Elsewhere
• Negative Sentiment: Clinical and legal overhang: Regeneron’s Phase 3 Fianlimab-Libtayo trial in advanced melanoma failed, prompting allegations that investors were misled about the study’s risks and protocol changes. Multiple law firms have announced or promoted securities class actions, citing the prior market-value loss. The litigation could increase reputational, financial and investor-confidence risks, although the announcements themselves do not represent findings of wrongdoing. Hagens Berman Regeneron investor alert

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.